Articles tagged with: ACE-011
News»

Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts' thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology -- which undoubtedly will host discussions of many potential new myeloma treatments -- it seems an appropriate time to go back to the experts' review from …
News, Opinion»

Multiple myeloma is the most frequent cancer to involve the skeleton, with up to 80 percent of patients having bone disease. Although fewer patients appear to have bone involvement more recently, it is still a major source of both complications and death among patients with myeloma.
Bone disease is so severe in myeloma because the normal bone remodeling process is disrupted. In normal individuals, damaged bone is removed by bone-destroying cells, the osteoclasts, and then bone is replaced by bone-forming cells, the osteoblasts. In myeloma, the number and activity of the bone-destroying …
NewsFlash »
Panobinostat In Combination With Velcade Shows Potential For Relapsed Multiple Myeloma (ASH 2009) – Researchers presented results at the American Society of Hematology Meeting (ASH) from a Phase 1 clinical trial that show that oral panobinostat (Farydak, LBH589) in combination with intravenous Velcade (bortezomib) has anti-myeloma effects. Researchers tested different doses of both panobinostat (10 mg to 30 mg) and Velcade (1.0 mg/m2 to 1.3 mg/m2). They found frequent blood-related adverse events, such as thrombocytopenia (low blood platelet count) and neutropenia (low white blood cell count). They concluded that dosing will be modified for future Phase 2/3 studies. For more information, please see abstract 3852 on the ASH meeting Web site.
Afinitor Is Safe In Relapsed And Refractory Multiple Myeloma; Drug Will Move To Phase 2 Clinical Trials (ASH 2009) – Afinitor (everolimus) is safe in relapsed and refractory multiple myeloma, according to preliminary results from a Phase 1/2 clinical trial presented at the 2009 Meeting of the American Society of Hematology (ASH). Afinitor was given orally at 5 mg to 10 mg daily. Researchers observed only one case of thrombocytopenia (low platelet count). A sufficient amount of anti-myeloma activity was observed for this drug to continue to Phase 2 testing, which puts more emphasis on the efficacy of the drug. For more information, see abstract 3850 on the ASH annual meeting Web site.
ACE-011 Increases Hemoglobin And Helps Build Bone In Multiple Myeloma Patients Receiving Chemotherapy (ASH 2009) – Preliminary results from a study presented at the 2009 Meeting of the American Society of Hematology (ASH) reveal that ACE-011 (sotatercept) increases hemoglobin (an iron-rich protein in red blood cells) and bone formation, decreases bone pain, and has anti-tumor activity in multiple myeloma patients receiving chemotherapy. A low hemoglobin count indicates a low red blood cell count (anemia), which is a common complication in multiple myeloma, as are bone lesions, and bone pain. All participants were on a regimen of melphalan (Alkeran), prednisone, and thalidomide (Thalomid). For more information, see abstract 749 on the ASH meeting Web site.
Researchers Demonstrate Feasibility And Safety Of Vaccine In Multiple Myeloma (ASH 2009) – Preliminary results from a Phase 1 clinical trial of a multiple myeloma vaccine, presented at the 2009 Meeting of the American Society of Hematology (ASH), indicate that using a vaccine in multiple myeloma is possible and that it is safe and tolerable. The study included 15 patients who had undergone peripheral blood progenitor cell transplantation – a treatment in which stem cells are collected from the bloodstream of a healthy donor and delivered to the myeloma patient after high-dose chemotherapy. The most frequent side effects were local skin reactions, typical of most vaccines. Further studies will evaluate the vaccine’s full potential. For more information, see abstract 1858 on the ASH meeting Web site.
For more information about myeloma-related studies covered at ASH, please see the Myeloma Beacon coverage of the ASH 2009 Meeting.
Resources, Treatments Under Development»
Brand Name: | |
Generic Name: | sotatercept |
Code Name: | ACE-011 |
Company: | Celgene and Acceleron Pharma |
FDA Clinical Phase: | 2 |
Description:
ACE-011 is a human fusion protein from the combination of Activin Receptor Type IIA and an antibody molecule. It is called a fusion protein because scientists have joined two different genes, each of which typically code for separate proteins. By …